| Term 
 | Definition 
 
        | CH 54 Cancer Chemotherapy Alkylating Agents   
| Transfer alkyl groups to various cellular constituents.  Alkylations of DNA within the nucleus probably represent the major interactions that lead to cell death. | Occur in rapidly growing tissues – bone marrow, GI tract, reproductive system   Nausea and vomiting | Cancer |    |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | CH 54 Cancer Chemotherapy Alkylating Agents   
| Transfer alkyl groups to various cellular constituents.Alkylations of DNA within the nucleus probably represent the major interactions that lead to cell death. | Occur in rapidly growing tissues – bone marrow, GI tract, reproductive system   Nausea and vomiting | Cancer |    |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | CH 54 Cancer Chemotherapy Alkylating Agents   
| Transfer alkyl groups to various cellular constituents.Alkylations of DNA within the nucleus probably represent the major interactions that lead to cell death. | Occur in rapidly growing tissues – bone marrow, GI tract, reproductive system   Nausea and vomiting | Cancer |    |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | CH 54 Cancer Chemotherapy Antimetabolites   
| Folate analog that inhibits dihdrofolate reductase (DHFR), interfering with the synthesis of tetrahydrofolate (THF), which is a key one-carbon carrier for purine nucleotide synthesis. | Mucositis, myelosuppression with neutropenia and thrombocytopenia   Hepatic toxicity | Breast cancer, head and neck cancer, osteogenic sarcoma, primary central nervous system lymphoma, non-Hodgkin’s lymphoma, bladder cancer, choriocarcinoma  |    |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | CH 54 Cancer Chemotherapy Antimetabolites   
| Inhibits purine nucleotide synthesis; incorporates triphosphate into RNA and DNA  | Myelosuppression, immunosuppression, hepatotoxicity  | Acute myelogenous leukemia (AML) |    |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | CH 54 Cancer Chemotherapy Antimetabolites   
| Inhibits thymidine synthase; incorporates 5-fluorouridine-5’-triphosphate (FUTP) into RNA resulting in alteration in RNA processing; incorporation of FdUTP into DNA resulting in inhibition of DNA synthesis  | Mucositis, bone marrow depression, neurotoxicity | Colorectal cancer, anal cancer, breast cancer, gastroesophageal cancer, head and neck cancer hepatocellular cancer |    |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | CH 54 Cancer Chemotherapy Mitotic Spindle Inhibitors   
| Inhibition of tubulin polyermization, which disrupts assembly of microtubules. This results in mitotic arrest in metaphase leading to cell death. | Myelosuppression, mucositis, alopecia, SIADH, vascular events | Hodgkin’s and non-Hodgkins’ lymphoma, germ cell cancer, breast cancer, Kaposi’s sarcoma |    |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | CH 54 Cancer Chemotherapy Mitotic Spindle Inhibitors   
| Inhibition of tubulin polyermization, which disrupts assembly of microtubules. This results in mitotic arrest in metaphase leading to cell death. | Neurotoxicity with peripheral neuropathy, paralytic ileus, myelosuppression, alopecia, SIADH  | Acute lymphoblastic anemia (ALL), Hodgkin’s and non-Hodgkin’s lymphoma, rhabdomyosarcoma, neuroblastoma, Wilms’ tumor |  |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | CH 54 Cancer Chemotherapy Mitotic Spindle Inhibitors   
| Acts as mitotic spindle poison by binding to microtubules and enhancing tubulin polymerization in the absence of microtubule-associated proteins and guanosine triphosphate.  Results in inhibition of mitosis and cell division. | Hypotension, arrhythmias, hypersensitivity, myelosuppression, peripheral sensory neuropathy  | Breast, non-small cell and small cell lung, ovarian, prostate gastroesophageal, bladder, head and neck |    |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | CH 54 Cancer Chemotherapy Topoisomerase Inhibitors   
| Inhibits topoisomerase II, which results in DNA damage through strand breakage induced by the formation of a ternary complex of drug, DNA, and enzyme | Hypotension, alopecia, myelosuppression | Non-small and small cell lung, non-Hodgkin’s lymphoma, gastric |    |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | CH 54 Cancer Chemotherapy Topoisomerase Inhibitors   
| Inhibit topoisomerase I, the key enzyme for cutting and re-ligating single DNA strands, resulting in DNA damage. | myelosuppression | Small cell lung, ovarian |    |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | CH 54 Cancer Chemotherapy Antibiotics   
| Cytotoxic action through 4 mechanisms: (1) Inhibits topoisomerase II (2) Binds to DNA through intercalation, which blocks synthesis of DNA and RNA, and causes DNA strand scission (3) Generation of free radicals (4) Bind to cellular membranes to alter fluidity and ion transport | Red urine (not hematuria), alopecia, myelosuppression, stomatitis    Cardiac toxicity: (acute) arrhythmias, pericarditis, myocarditis; (chronic) cardiomyopathy and heart failure | Breast, Hodgkin’s and non-Hodgkin’s lymphoma, soft tissue sarcoma, ovarian, non-small and small cell lung, thyroid, Wilms’ tumor, neuroblastoma |    |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | CH 54 Cancer Chemotherapy Antibiotics   
| Oxygen free radicals bind to DNA causing single- and double-strand DNA breaks | Allergic reactions, fever, hypotension, skin toxicity, pulmonary fibrosis, mucositis, alopecia | Hodgkin’s and non-Hodgkin’s lymphoma, germ cell, head and neck |    |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | CH 54 Cancer Chemotherapy Antibiotics   
| Acts as an alkylating agent and forms cross-links with DNA; formation of oxygen free radicals, which target DNA | Myelosuppression, mucositis, anorexia and fatigue, hemolytic-uremic syndrome | Superficial bladder, gastric, breast, non-small cell lung, head and neck |    |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | CH 54 Cancer Chemotherapy Hormonal Agents   
| Androgen receptor antagonist | Mild gynecomastia, reversible hepatic toxicity | Prostate cancer |    |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | CH 54 Cancer Chemotherapy Hormonal Agents   
| Selective estrogen receptor modulator (SERM); competitive partial agonist inhibitor of estradiol at the estrogen receptor   Estrogen receptor antagonist (breasts) Estrogen receptor agonist (bones) | Hot flushes, nausea, vomiting | Palliative treatment of breast cancer in postmenopausal women and chemoprevention of breast cancer in high-risk women; prevent osteoporosis |    |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | CH 54 Cancer Chemotherapy Hormonal Agents   
| Glucocorticoid  | Hypertension, fluid retention, diabetes, ↑susceptibility infection Cataracts, fat redistribution, glaucoma, muscle wasting, peptic ulcers | Rx: control proliferation of corticosteroid sensitive tumors (Hodgkin's, non-Hodgkin's, etc.) |    |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | CH 54 Cancer Chemotherapy Hormonal Agents   
| GnRH receptor agonist; suppresses FSH & LH release in the long-term | Gynecomastia, hot flashes, impotence | prostate |    |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | CH 54 Cancer Chemotherapy Hormonal Agents   
| Selective nonsteroidal inhibitor of aromatase, the enzyme required for estrogen synthesis | Fatigue, hot flashes, arthralgias | Breast cancer |    |  | 
        |  |